Lv11
76 积分 2022-06-20 加入
Glofitamab plus polatuzumab vedotin: a novel safe, and highly effective chemotherapy-free regimen for pediatric relapsed/refractory B-cell non-Hodgkin lymphoma
3小时前
已关闭
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study
21天前
已关闭
The treatment of marginal zone lymphoma
3个月前
已完结
The treatment of marginal zone lymphoma
3个月前
已完结
Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL
5个月前
已完结
Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
5个月前
已完结
Prior transplantation and idecabtagene vicleucel in multiple myeloma: a secondary analysis of CIBMTR data
5个月前
已关闭
Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma
5个月前
已关闭
Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML
8个月前
已完结
Spontaneous and granulocyte–colony-stimulating factor-enhanced marrow response and progenitor cell mobilization in mice after myocardial infarction
10个月前
已完结
皖公网安备34019202002308
